Disclosure of Islamic Social Reporting of Islamic Banks in Indonesia with Analysis of Profitability and Size for 2016-2020
Journal Markcount Finance · 2023
DOI: 10.55849/jmf.v1i1.54 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal Markcount Finance, 2023. Verfasst von Hussein Adema und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Abstract (Originalsprache)
Islamic Social Reporting (ISR) is an index of social accountability disclosure whose indicators refer to Islamic ethical principles. Islamic banking operates by Sharia principles. Therefore the disclosure of ISR in Islamic banking must be within the corridors of Islamic theology. This study uses the E-Views software to identify the factors that influence exposure to Islamic Social Reporting (ISR) in Islamic banking in Indonesia. The factors examined in this study are company performance and company size towards Islamic Social Reporting. The results of this study show that financial performance proxied by ROA has no effect on ISR with a calculated T value of 1.338357, and financial performance proxied by NPF has no impact on Islamic Social Reporting with an estimated T value of 1.405019. Company size is a proxy for the Size that affects Islamic Social Reporting, with a T-test result of 3.077773
Zitieren
APA
Adema, H., Tariq, K., & Carmelo, D. (2023). Disclosure of Islamic Social Reporting of Islamic Banks in Indonesia with Analysis of Profitability and Size for 2016-2020. Journal Markcount Finance. https://doi.org/10.55849/jmf.v1i1.54
Vancouver
Adema H, Tariq K, Carmelo D. Disclosure of Islamic Social Reporting of Islamic Banks in Indonesia with Analysis of Profitability and Size for 2016-2020. Journal Markcount Finance. 2023. doi:10.55849/jmf.v1i1.54
BibTeX
@article{Adema2023,
author = {Adema, Hussein and Tariq, Kubota and Carmelo, Dumaz},
title = {Disclosure of Islamic Social Reporting of Islamic Banks in Indonesia with Analysis of Profitability and Size for 2016-2020},
journal = {Journal Markcount Finance},
year = {2023},
doi = {10.55849/jmf.v1i1.54}
}
EUVIMED